Healthcare

...

<!-- Name:DistributionId Value:8756066 --> ...

Spine Biologics Market3 PORTLAND, OR, UNITED STATES, September 5, 2023/EINPresswire.com/ -- Allied Market Research has recently released a comprehensive research study titled "Global Spine Biologics Market: Outlook and Forecast 2023-2030." This report thoroughly evaluates market risks, highlights opportunities, and provides strategic and tactical decision-making support for the period from 2023 to 2030. The market study...

Thursday, April 19, 2022, New Delhi: Signia, a leader in the hearing aid industry, today announced the launch of ‘Brilliant Sound Galaxy (BSG)’, the first of its kind interactive concept store in the capital city Delhi, where consumers can self-discover aspects of hearing, self-screen their hearing, experience hearing live with hearing aids and take an informed decision to enhance...

Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023A novel proprietary genetic vaccine adjuvant was presented at Evaxion’s R&D Day in May. The technology is an integral part of the next-generation cancer vaccine, EVX-03, planned for phase 1 clinical trial application in Q4 2023*Promising results...

-- ENA-001, a brand new chemical entity with a novel mechanism of motion, is being developed as an agnostic respiratory stimulant to be used in a number of affected person populations experiencing acute respiratory melancholy -- -- Development is below approach of intramuscular formulation for therapy of group drug overdose and as a medical countermeasure for mass...

SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, today announced the presentation of data demonstrating the packaging and delivery of its proprietary small nuclear RNA (snRNA) platform using adeno-associated virus (AAV). The poster describes specific applications of this...

On-Demand Replays from Continuing Education Company (CEC) Offer Convenient, High Quality Primary Care Continuing Medical Education (CME) We are so pleased to offer On-Demand Replays, enabling healthcare professionals to access high-quality CME content that aligns with their busy schedules.  ”— Walter Ejnes, CHCP, President CECPALM COAST, FL, UNITED STATES, November 19, 2023 /EINPresswire.com/ -- Continuing Education...

Interim Analysis for KALAHARI trial planned by Year-End 2022 with Full Top-Line Data Expected in Second half of 2023 Leuven, BELGIUM, Boston, MA, US – November 18, 2022 – 10:00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders,...

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profilePrimary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early...